Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences

Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences

MT newswireMT newswire2026/09/15 14:16
10:16 AM EDT, 09/15/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) has completed its acquisition of privately held Actio Biosciences for $820 million upfront, the company said Tuesday. The acquisition adds ABS-1230, a clinical-stage investigational therapy for KCNT1-related epilepsy, to Jazz Pharmaceuticals' pipeline. ABS-1230 is an oral, small-molecule KCNT1 inhibitor being developed for KCNT1-related epilepsy. Price: 244.75, Change: -1.12, Percent Change: -0.46
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!